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Use of a Granulocyte Immunofluorescence Assay Designed for
Humans for Detection of Antineutrophil Cytoplasmic Antibodies in
Dogs with Chronic Enteropathies
J. Florey , A. Viall, S. Streu, V. DiMuro, A. Riddle, J. Kirk, L. Perazzotti, K. Affeldt, R. Wagner,
S. Vaden, T. Harris, and K. Allenspach
Background: Perinuclear antineutrophil cytoplasmic antibodies (pANCA) previously have been shown to be serum mark-
ers in dogs with chronic enteropathies, with dogs that have food-responsive disease (FRD) having higher frequencies of
seropositivity than dogs with steroid-responsive disease (SRD). The indirect immunofluorescence (IIF) assay used in previous
publications is time-consuming to perform, with low interobserver agreement.
Hypothesis/Objectives: We hypothesized that a commercially available granulocyte IIF assay designed for humans could
be used to detect perinuclear antineutrophil cytoplasmic antibodies in dogs.
Animals: Forty-four dogs with FRD, 20 dogs with SRD, 20 control dogs, and 38 soft-coated wheaten terrier (SCWT) or
SCWT-cross dogs.
Methods: A granulocyte assay designed for humans was used to detect pANCA, cANCA, and antinuclear antibodies
(ANA), as well as antibodies against proteinase-3 protein (PR-3) and myeloperoxidase protein (MPO) in archived serum
samples.
Results: Sensitivity of the granulocyte assay to predict FRD in dogs was 0.61 (95% confidence interval (CI), 0.45, 0.75),
and specificity was 1.00 (95% CI, 0.91, 1.00). A significant association was identified between positive pANCA or cANCA
result and diagnosis of FRD (P < 0.0001). Agreement between the two assays to detect ANCA in the same serum samples
from SCWT with protein-losing enteropathy/protein-losing nephropathy (PLE/PLN) was substantial (kappa, 0.77; 95% CI,
0.53, 1.00). Eight ANCA-positive cases were positive for MPO or PR-3 antibodies.
Conclusions and Clinical Importance: The granulocyte immunofluorescence assay used in our pilot study was easy and
quick to perform. Agreement with the previously published method was good.
Key words: Antineutrophil cytoplasmic antibodies; Chronic enteropathy; Food-responsive disease; Indirect
immunofluorescence.
Antineutrophil cytoplasmic antibodies (ANCA) aredirected against neutrophil granule components.1
The location of antigen–antibody complexes after incu-
bation allows these antibodies to be classified as
perinuclear antineutrophil cytoplasmic antibodies
(pANCA) or cytoplasmic antineutrophil cytoplasmic
antibodies (cANCA) when visualized using indirect
immunofluorescence (IIF). Specific antigens can be fur-
ther identified by testing for antibodies against
myeloperoxidase protein (MPO) and proteinase-3
protein (PR-3). These proteins are enzymes that may be
involved in neutrophil degranulation and generation of
reactive oxygen species, among other functions.2,3
After increasing use in the human medical field,
ANCA have been documented in diseases of dogs associ-
ated with an inappropriate immune response, including
canine inflammatory bowel disease, protein-losing
enteropathy/nephropathy (PLE/PLN), immune-
mediated hemolytic anemia, and vasculitis-related ill-
ness.4–7 Antineutrophil cytoplasmic antibodies have been
documented in patients with neoplastic and infectious
diseases.6,8 Chronic enteropathies are well documented
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in veterinary medicine and have been divided into dis-
eases that are responsive to dietary management alone
(termed “food-responsive disease,” [FRD]), antibiotic
therapy (termed “antibiotic-responsive disease”), or dis-
eases that require immunosuppressive drugs for control
of clinical signs (termed “steroid-responsive disease,”
[SRD]).9 The presence of pANCA in dogs with chronic
enteropathies has been suggested to correlate with a pos-
itive response to management with strict elimination diet
implementation alone. Despite use as a potential marker
for FRD, no correlation with clinical disease severity
scoring was found.10 Studies involving a cohort of soft-
coated wheaten terriers (SCWT) and SCWT-beagle
crossbred dogs with PLN/PLE indicated that antibodies
appeared up to 2 years before development of clinically
relevant disease, suggesting possible use of ANCA to
predict onset of disease.5 Titers for ANCA remained
positive once identified. These various studies suggest
that ANCA testing could be utilized for a number of
immune-mediated disease syndromes although an assay
designed for dogs is not currently widely available.
Previously reported methods for analysis of ANCA in
veterinary medicine have involved the use of relatively
time-consuming laboratory techniques, with a need for
collection of serum from donor dogs from which neu-
trophils were isolated and harvested using centrifugation
of blood with polymorph preparation designed to isolate
polymorphonuclear leukocytes.4,a Granulocytes subse-
quently were fixed with ethanol before sample testing.
Neutrophil isolation produced inconsistent results
because of variability in canine granulocyte purification,
and interobserver variation in immunofluorescence result
interpretation was reported to be high, adding to the
inherent subjectivity of the test.4 A commercially avail-
able assay for ANCA could decrease the time needed to
perform the assay while ensuring improved reliability and
consistency of results. By the previously reported ANCA
assay, 8–10 samples could be run per day, including a pos-
itive and negative control.
The primary aim of our pilot study was to evaluate
whether a commercially available granulocyte IIF assay
designed for use in humans could be used to detect
ANCA in dogs. We hypothesized that pANCA would
be detectable in patients with FRD. In addition, we
hypothesized that agreement between the results from
the canine granulocyte assay and the assay designed for
humans would be high when using samples from dogs
tested using both methods.
Materials and Methods
Patient Selection
Archived serum samples from 44 dogs of different breeds with
FRD, 20 dogs of different breeds with SRD, and 20 healthy dogs
were included in the study. Patients with FRD were defined as
those that had suffered from chronic diarrhea for >4 weeks and
had a diagnosis based on exclusion of other potential underlying
diseases, based on results of CBC, serum biochemistry profile,
fecal evaluation, and abdominal ultrasound examination. These
dogs had all had gastrointestinal biopsy samples collected at the
time of serum sample submission. All dogs in the FRD group had
been treated using a strict exclusion diet at the discretion of the
clinician in charge of the case and had responded favorably, with
normalization of clinical signs within 2 weeks. These patients then
were maintained on the exclusion diet for at least 8 weeks, without
relapse of clinical signs.
All dogs within the SRD group had undergone comprehensive
diagnostic investigations, including CBC, serum biochemistry pro-
file, abdominal ultrasound examination, and endoscopy with gas-
trointestinal biopsies. Dogs with SRD were defined as those that had
undergone at least 1 unsuccessful dietary and antimicrobial trial with
either metronidazole or tylosin, at clinician discretion, for at least 4
weeks, and required immunosuppressive therapy to control their
clinical signs. An unsuccessful dietary trial was defined as a trial that
did not lead to substantial improvement or resolution of clinical
signs within 2–4 weeks.11 A number of combinations of pred-
nisolone, cyclosporine, and azathioprine treatment were included in
this group. In all dogs with FRD and SRD, endoscopic biopsy sam-
ples from some combination of stomach, duodenum, colon, and
ileum had been analyzed. Biopsy samples were evaluated by an expe-
rienced pathologist in conjunction with the World Small Animal
Veterinary Association (WSAVA) guidelines.12
All healthy control dogs had undergone complete physical
examination, had no history of diarrhea, and had had an unre-
markable comprehensive laboratory evaluation.
In addition, 38 serum samples from a colony of SCWT or
SCWT-Beagle crossbred dogs with PLE/PLN at North Carolina
State University were analyzed. These samples previously had been
evaluated for the presence of ANCA using the published method
for dogs4 and had residual samples available for testing that had
been stored at 80 C. Detection of ANCA is possible after several
freeze–thawing cycles. Samples are stable over years in serum fro-
zen at temperatures below 20°C (Allenspach, unpublished obser-
vations). Details regarding these 38 patients can be found in a
previously reported study.5 Agreement between the two methods
was assessed by testing a subset of 10 samples by the same person
(KA), using both assays.
All serum samples used in our study consisted of residual diag-
nostic blood samples. The archived serum and biopsy samples for
this study had been taken for diagnostic purposes only. The study
was approved by the Royal Veterinary College Ethics and Welfare
Committee.
Sample Processing and Indirect Immunofluorescence
Technique
An assayb not previously reported in the veterinary literature
for dogs was utilized for analysis of antibodies in the serum sam-
ples. Granulocyte mosaic slides containing biochips with human
granulocytes fixed in ethanol, human granulocytes fixed in forma-
lin, myeloperoxidase protein (MPO), proteinase-3 protein (PR-3),
and HEp-2 cells were used. This combination allows detection of
pANCA, cANCA, and antinuclear antibodies (ANA) on the same
slide as well as enabling several patient samples to be analyzed at
1 time. It also allows assessment for antibodies to specific antigens
(MPO and PR-3) by provision of antigen-specific substrates. The
method of performing the assay is standardized, and each biochip
is identical in appearance and content. Up to 40 samples can be
run in 1 day.
The novel assay was performed according to manufacturer’s
instructions. Briefly, patient serum was diluted 1:10 using 0.2%
phosphate-buffered saline (PBS)–Tween. Biochip slides were incu-
bated with 30 lL of diluted serum for 30 minutes at room temper-
ature. After washing with PBS–Tween, 25 lL of fluorescein
isothiocyanate (FITC)-labeled goat anti-dog immunoglobulin was
added to each reaction field. After further incubation for 30 min-
utes and washing, the slides were embedded in glycerol medium,
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covered with a cover glass and each biochip was fully evaluated
with a 4-quadrant technique with a fluorescence microscope at
200–4009 magnification by two independent observers who were
trained in the technique by an operator with extensive previous
IIF experience. Results were interpreted as positive or negative by
each observer. A third experienced reviewer was used if results
were ambiguous. Human serum positive and negative controls
were utilized as provided by the manufacturer for each sample.
Statistical Analysis
Data analysis was performed by commercial statistical softwarec
. A chi-square test was used to determine the association of a posi-
tive ANCA result with the diagnosis of FRD. Sensitivity and
specificity for the correct detection of FRD or SRD with 95% CI
were calculated for use of the new assay designed for humans in
dogs. Agreement between the previously published granulocyte
ANCA assay for dogs and the new granulocyte assay for humans,
performed on the same samples and by the same person, was cal-
culated by the unweighted kappa statistic. Significance for all sta-
tistical testing was set at P < 0.05. Interpretation of the kappa
statistic was performed as reported previously, with <0 represent-
ing poor agreement and >0.8 representing almost perfect
agreement.13
Results
Of the dogs diagnosed with FRD, 22 were female
and 22 were male. Neuter status was not always
recorded. There were 39 purebred dogs included and
five crossbred dogs. Dogs were all of different individual
breeds with only the French bulldog and German Shep-
herd dog included more than once (4 and 3 times,
respectively). Their ages ranged from 8 months to 9
years (mean age, 2.6 years). All histopathology findings
included evidence of inflammatory change in at least
two anatomical sections of the gastrointestinal tract.
The inflammatory changes were predominantly lympho-
plasmacytic in nature with no infectious agents or neo-
plastic infiltrates reported. Variable degrees of villous
atrophy and lymphoid hyperplasia were reported.
Of the 20 dogs diagnosed with SRD, 3 were cross-
bred dogs and 17 were purebred dogs. Their ages ran-
ged from 2 to 13 years (mean age, 7.1 years).
Histopathologic evaluation had identified lymphoplas-
macytic inflammatory changes in at least 2 anatomic
sections of the gastrointestinal tract with variable
degrees of villous atrophy and lymphoid hyperplasia.
No infectious agents or neoplastic infiltrates were
reported for any dog.
Of the control dogs, 5 were crossbred dogs, 4 were
beagles, and 11 were purebred dogs. Their ages ranged
from 1 to 13 years (mean age, 6.1 years). Data from the
SCWT/SCWT-Beagle crossbred dogs were described
previously.5
Accuracy of the Granulocyte Assay Designed for
Humans to Diagnose FRD and SRD in Dogs
By the new assay designed for humans, all 20 samples
from healthy dogs were negative for ANCA and ANA.
All 20 dogs with SRD also were negative for ANCA
and ANA. Of the 44 dogs with FRD, 27 (61.4%) were
positive for antibodies to pANCA (Fig 1) or cANCA
(Fig 2) by the new method (Table 1). Sensitivity of the
granulocyte assay designed for humans to predict FRD
in dogs was 0.61 (95% CI, 0.45, 0.75), and specificity
was 1.00 (95% CI, 0.91, 1.00). Significant association
between a positive ANCA result and a diagnosis of
FRD was identified (P < 0.0001). In 8 positive cases,
either MPO or PR-3 autoantibodies were identified on
the biochips with 5 samples positive for PR-3 and three
samples positive for MPO.
Comparison of the Granulocyte Assay Designed for
Humans with the Granulocyte Assay for Dogs using
the Same Canine Serum Samples
Of the 38 SCWT and SCWT-crossbred dog serum
samples, 31 tested positive for ANCA by the previously
published granulocyte method for dogs. By the granulo-
cyte assay designed for humans described here, 28 of
Fig 1. Positive canine pANCA IIF by the human granulocyte
assay and FITC-labeled goat anti-dog immunoglobulin. Green flo-
rescence indicates a positive result. 9400 magnification.
Fig 2. Positive canine cANCA IIF by the human granulocyte
assay and FITC-labeled goat anti-dog immunoglobulin. Green flo-
rescence indicates a positive result. 9400 magnification.
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those same dog samples tested positive (Table 2).
Agreement between the 2 assays to detect ANCA in
serum of the same samples was substantial
(kappa = 0.77; 95% CI, 0.53, 1.00).13
Discussion
Results of our study indicate that pANCA and
cANCA can be detected using human granulocyte
mosaic biochip slides. This method of testing was help-
ful to differentiate patients with FRD from those with
SRD or those without disease, with no positive results
documented for either of the latter testing categories.
Sensitivity and specificity to diagnose FRD or SRD by
this method was similar to previously published
results.3,7
Because IIF interpretation is subjective, improved
procedure and ease of interpretation of results is para-
mount for optimal use of such a test. Use of a test with
purified granulocytes adhered on the slides as well as
the use of human serum positive and negative controls
provided by the company made interpretation easier
than with the previously published method. Purification
of canine granulocytes before performing the
immunofluorescence assay was not required, which
shortened the time taken to perform the assay to <1
day. The design of the new assay allowed several
patient samples to be analyzed at 1 time, theoretically
improving reliability and throughput of patient samples.
Agreement between the 2 assay methods was substan-
tial with a calculated kappa statistic of 0.77. Although
this agreement is good, it does indicate that in approxi-
mately 20% of cases, the assays did not agree. This dis-
crepancy is demonstrated in Table 2. The possibility of
this disagreement should be taken into consideration
when interpreting results using either ANCA test. Cal-
culated sensitivity and specificity of the methodology
designed for humans indicates that the test appears to
be less sensitive than the method using dog granulo-
cytes, although for the purposes of our study it was
only used to assess for ANCA in samples of SCWT/
SCWT-crossbred dogs with PLE/PLN.4 Although the
sensitivity of this test was only 0.61, the primary aim of
our study was to report the use of a granulocyte test
designed for humans in dogs, and not to conclusively
document clinical utility of the test in a large cohort of
patients. Additional prospective testing now should be
performed to assess the ability of this test to differenti-
ate disease etiologies.
Assuming there is a loss of sensitivity with the new
assay, it is possible that by using human granulocytes
instead of dog granulocytes, some antigens are not
being detected, therefore decreasing sensitivity of the
test. Sequence homology between canine and human
MPO is 88% when the sequences are compared.14 The
amino acid sequence of canine PR-3 currently is not
available and comparison to the human sequence can-
not be made. Although canine and human MPO are
expected to exhibit close homology, there is a possibility
that some epitopes of canine MPO may not be detected
by the assay designed for humans, leading to false-nega-
tive results. It is also possible that differences in prepa-
ration of slides and the drying and fixation process may
have affected the sensitivity results, although every
effort was made to perform the analyses by the same
methodology under consistent conditions.
The possibility of false positives also cannot be con-
clusively excluded. There is no accepted gold standard
method available to conclusively document the presence
or absence of ANCA in veterinary patients. This situa-
tion hampers evaluation of agreement between true-
positive and true-negative results, and this possibility
should always be considered during test result interpre-
tation. Once specific antigens for ANCA are identified,
such as PR-3 and MPO, Western blot to detect anti-
bodies against the canine proteins could be used as a
gold standard.
In 8 patients, the antigen being targeted also could be
identified. As a consequence of the small number of sam-
ples in which this was possible, the clinical relevance of
this finding remains unclear and requires further clinical
study. In human patients with ulcerative colitis, pANCA
are more commonly identified in patients with a more
clinically aggressive disease course.15 The PR-3 autoanti-
bodies may be of importance in ulcerative colitis, and
their presence has been documented in this disease.16
Due to the nature of our study, prospective follow-up on
patients with ANCA was not possible. The small num-
ber of patients in which specific antigen identification
was observed may further support a loss of sensitivity by
Table 1. ANCA results by the new human granulocyte
assay.
Human granulocyte ANCA assay
Positive Negative
CTR 0 20
SRD 0 20
FRD 27 17
ANCA, antineutrophil cytoplasmic antibodies; CTR, healthy
control dogs; FRD, dogs with food-responsive disease; SRD, dogs
with steroid-responsive disease.
Table 2. Comparison of results between the previously
published canine granulocyte ANCA assay and the new
human granulocyte ANCA assay using the same sam-
ples from SCWT with PLE/PLN.
Canine
granulocyte
ANCA assay
TotalPositive Negative
Human granulocyte
ANCA assay
Positive 28 0 28
Negative 3 7 10
Total 31 7 38
ANCA, antineutrophil cytoplasmic antibodies; SCWT, soft-
coated wheaten terrier; PLE/PLN, protein-losing enteropathy/pro-
tein-losing nephropathy.
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use of an assay designed for humans. Alternatively, the
underlying antigen may be different in the majority of
affected dogs. In humans, the main ANCA proteins that
have been identified are lactoferrin, elastase and bacteri-
cidal increasing protein.16 Further research to identify
the specific proteins targeted by canine ANCA is
required, although they may be similar to those docu-
mented in human patients.
In conclusion, this granulocyte ANCA assay designed
for use in humans can be used with canine serum to
assess for the presence of ANCA, with good agreement
between the two assays when performed on the same set
of serum samples. This standardized method was easy to
perform and did not require donor dogs for granulocyte
extraction. In a subset of these patients, specific antigens
could be identified that may allow further research into
a variety of immune-mediated diseases in dogs. Despite
a lack of sensitivity, this assay appears to be highly spe-
cific. The availability of a commercial test allows addi-
tional large studies on ANCA to be performed,
evaluating its potential role in clinical case investigation.
Footnotes
a Polymorphprep medium, Axon Lab AG, Oslo, Norway
b EUROIMMUN, Ashville House, Wimbledon, London
c IBM SPSS Statistics, version 22, Armonk, NY
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